Related Experiment Video

Updated: May 11, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma

Soley Bayraktar1, Caio M Rocha-Lima

  • 1Soley Bayraktar, Departments of Medical Oncology, Mercy Cancer Center, Ardmore, OK 73401, United States.

World Journal of Clinical Oncology
|May 23, 2013
PubMed

Insights

Targeted therapies offer new hope for advanced non-small-cell lung cancer (NSCLC) patients. This review summarizes promising biologic targets and their clinical trial status, potentially improving survival and quality of life.

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Trials

Background:

  • Non-small-cell lung cancer (NSCLC) is a leading cause of cancer mortality in the US.
  • Platinum-based chemotherapy offers modest survival benefits for advanced NSCLC.
  • Aberrant molecular pathways in NSCLC drive the need for novel therapeutic strategies.

Purpose of the Study:

  • To review currently investigated biologic targets in NSCLC.
  • To discuss the clinical trial status of these targeted agents.
  • To explore the potential for future targeted therapy development in NSCLC.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of ongoing clinical trials for NSCLC targeted therapies.
  • Synthesis of data on molecular targets and their therapeutic potential.

Main Results:

  • Several molecular targets are under investigation for NSCLC treatment.
  • Targeted therapies are showing promise in clinical trials.
  • Biomarker-driven approaches are reshaping NSCLC treatment paradigms.

Conclusions:

  • Targeted therapies represent a significant advancement in NSCLC treatment.
  • Continued research into novel biologic targets is crucial for improving patient outcomes.
  • Personalized medicine approaches hold great potential for managing NSCLC.
Keywords:
Anaplastic lymphoma kinaseBRAFEpidermal growth factor receptorMolecular targeted therapyNon-small cell lung cancerTyrosine kinase inhibitorsVascular endothelial growth factor

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...